OssDsign AB (FN Stockholm:OSSD), a developer and provider of next generation bone replacement products, announced on Monday that its clinical study TOP FUSION is fully enrolled and patient follow-up will continue to run over 24 months.
This trial will primarily evaluate the safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery.
OssDsign Catalyst is a synthetic bone graft based on a patented nanocrystalline solution that stimulates the formation of healthy bone. It received FDA clearance in 2020 and was launched on the US market in August 2021.
According to the company, the study's primary endpoint will be assessed by the rate of bone fusion as well as a lack of device-related adverse events.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project